We summarize the evidence on the new strategies for coronary artery bypass grafting (CABG). Hybrid CABG implies surgical grafting of the left anterior descending artery and percutaneous treatment of the other target vessels, with the promise of combining the durable benefits of surgery with the less invasive approach of percutaneous coronary interventions. Robotic CABG and minimally invasive CABG are performed through minimal incision or port access with dedicated equipment and instruments. Anaortic coronary artery bypass refers to offpump CABG using only in-situ grafts. The use of multiple arterial grafts has been shown to improve patency and is potentially associated with better clinical outcomes. All these techniques require dedicated training and are more complex than conventional CABG but can significantly improve the results of surgery. Validation of the results of these new approaches in large randomized trials is a priority for the surgical community.
I
n April 1968, Renee Favaloro published the first series of aortocoronary bypass operations. 1 In the 50 years since that landmark publication, coronary artery bypass surgery (CABG) has been enthusiastically embraced by cardiac surgeons all around the world. Currently, according to the most recent data of the Society of Thoracic Surgeons Database, the majority of adult cardiac surgery procedures in the United States are CABG operations. 2 In the 5 decades since Favaloro's initial procedure, CABG has witnessed substantial changes and evolutions. Continuous technical and technological improvements have made the operation safer and less invasive. Hybrid revascularization and robotic, minimally invasive, and anaortic CABG represent the extreme of the evolution of the procedure originally described in 1968. All the new techniques share the issue of increased technical and logistical complexity and more limited supporting evidence and applicability compared with the standard operation, so their adoption by the surgical community has been limited ( Figure 1 ; data for minimally invasive CABG provided by the Society of Thoracic Surgeons Access and Publication Research Program, unpublished data, 2018). [3] [4] [5] In this article, we review these techniques and provide a summary of the state of the art of the different approaches.
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November 6, 2018 2161 performed in the following databases from inception to present: Ovid MEDLINE, Ovid EMBASE, the Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials), and Cochrane Methodology Register. Search key words included "myocardial revascularization" in combination with "endoscopic," "robotic," "minimally invasive," "anaortic," and "hybrid." Relevant abstracts were reviewed. and the related-articles function was used for all included articles. References for all selected studies were cross-checked. The writing group selected the most relevant articles according to both methodological and clinical considerations. Observational series were considered only in the absence of data from randomized controlled trials.
HYBRID REVASCULARIZATION
Integrating the positive features of both percutaneous coronary intervention (PCI) and CABG has been the fundamental rationale of hybrid coronary revascularization (HCR). The HCR strategy combines grafting of the left anterior descending coronary artery (LAD) with the left internal thoracic artery (LITA) and PCI of non-LAD coronary stenoses. Essentially, stents are substituted for saphenous vein grafts (SVGs) for non-LAD lesions, and the surgical LITA-to-LAD bypass is performed through a limited-access, sternotomy-sparing approach. In B, the size of the circle is proportional to the number of articles published for each technique up to June 2018. AnCABG indicates anaortic coronary artery bypass surgery; CABG, coronary artery bypass surgery; HCR, hybrid coronary revascularization; and MAG, multiarterial grafting. The rationale for choosing HCR over PCI or CABG alone stems from the hypotheses that the LITA-to-LAD bypass graft may contribute the majority of the survival advantage provided by CABG, the advantage of additional arterial grafts (AGs) over PCI to non-LAD targets is limited, and the early restenosis rate of non-LAD vessels after PCI with drug-eluting stents may not be significantly different from the early occlusion rate of SVGs.
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To date, the published data on HCR must still be considered hypothesis generating. The collective published work constitutes ≈2000 patients in HCR registries, cohort studies comparing CABG and HCR, and 1 randomized trial (Table 1) . Nonetheless, the data from these studies suggest that HCR can potentially provide a higher degree of durability, symptom relief, and survival relative to 3-vessel stenting; afford a stroke rate comparable to PCI and lower than standard CABG by not manipulating the ascending aorta; and offer a very low infection rate, transfusion rate, and recovery time by minimizing chest wall trauma and avoiding median sternotomy.
Hybrid revascularization with >1 AG and PCI has also been described.
To date, only 1 randomized trial of HCR versus CABG has been reported: POL-MIDES HYBRID (Prospective Randomised Pilot Study Evaluating the Safety and Efficacy of Hybrid Revascularisation in MultiVessel Coronary Artery Disease) compared off-pump CABG and sternotomy-sparing LITA to LAD plus PCI-drug-eluting stents to the non-LAD lesions in patients with multivessel disease. 23 In both groups, full revascularization was achieved, and similar outcomes at the 1-year follow-up were reported. The recently published 5-year results confirmed similar mortality and incidence of myocardial infarction, repeat revascularization, stroke, and the composite of major adverse cardiac and cerebrovascular events in the HCR and CABG groups. 27 No randomized controlled trial to date has compared HCR with multivessel PCI.
The National Heart, Lung, and Blood Institutefunded Hybrid Observational Study 28 is the first multicenter prospective cohort study of practice patterns and outcomes of patients undergoing HCR. The 200 HCR-eligible patients who received HCR and 98 HCReligible patients who received multivessel PCI with drug-eluting stents were enrolled at 11 sites in the United States. Similar risk-adjusted major adverse cardiovascular or cerebrovascular event rates at 12 months were reported in the 2 groups, with rates diverging (although not statistically significantly) at the18-month follow-up in favor of patients who received HCR. 28 Good concordance between cardiac surgeons and interventional cardiologists in terms of anatomic eligibility for HCR was found, with disagreement in only 3% of cases. Such consensus supports the feasibility of conducting a comparative-effectiveness trial of HCR. The ongoing National Heart, Lung, and Blood Institute-funded randomized Hybrid Coronary Revascularization Trial was informed by the Hybrid Observational Study and is intended to compare outcomes with HCR and PCI in patients with moderate SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score with a proximal LAD lesion and a second lesion in a non-LAD territory.
The timing of the surgical and PCI procedures during HCR can vary from simultaneous 1-stage procedures to CABG-first or PCI-first approaches. The advantages and disadvantages of each strategy remain only theoretical because of the almost complete absence of comparative studies. In clinical practice, most of the HCRs are performed as a staged procedure rather than simultaneously. The decision of offering PCI first or CABG first is part of the heart team decision: A PCI-first approach is suitable for acute coronary syndrome with a non-LAD culprit lesion. A CABG-first approach, on the other hand, avoids the potential for increased postoperative bleeding from the dual antiplatelet therapy, allows confirmation of the patency of the LAD graft, and provides protection of the LAD territory during PCI of high-risk non-LAD lesions.
A small observational comparison has found no differences in postoperative and midterm outcomes between the PCI-first and CABG-first approaches. 24 
ROBOTIC CABG
The use of robotic telemanipulation for CABG was first reported in the late 1990s. After an initial burst of enthusiasm, the adoption of robotic coronary surgery has remained very limited. According to a report from the Society of Thoracic Surgeons Adult Cardiac Surgery Database, robotic technology was used in only 0.97% of all CABG procedures performed in the United States from 2006 to 2012. 26 The high cost of the robot and its necessary disposable tools, the longer operative time, and the need for specific training in the absence of a clear demonstration of improved outcomes are probably the main reasons for this low adoption among the surgical community.
Today, the term robotic-assisted CABG can refer to a number of different procedures, as shown in Figure 2 .
Currently, the most commonly performed operation entails robotic harvesting of the LITA, with subsequent anastomosis to the LAD being completed by direct access via a small thoracotomy (minimally invasive direct CABG). Interest in this procedure has recently been renewed by the growing adoption of the hybrid approach described in the previous section, because most centers use robotic minimally invasive direct CABG for the surgical part of the hybrid procedure. 28 The articulated instrumentation and stereoscopic vision provided by the robotic technology facilitate harvesting of the internal thoracic artery (ITA). Opening the pericardium and identifying the target vessel with the robotic instruments minimizes the extension of the subsequent thoracotomy. The learning curve for robotic-assisted coronary surgery seems to be relatively short, especially in those institutions that already have experience with off-pump CABG techniques.
Bilateral ITA CABG through a minithoracotomy with robotic harvesting has also been described.
A further step toward minimally invasive CABG with much more limited applicability is robotic total endo- scopic coronary artery bypass (TECAB). TECAB is performed without an open incision through port access. Arrested TECAB incorporates peripheral cannulation for cardiopulmonary bypass and cardioplegic arrest with an "endoclamp." The anastomosis is performed entirely within the closed chest with robotic instruments (Figure 3) . Conversion rates to open surgery remain relatively high because of the complexity of the cannulation, the challenges of working entirely within the closed intrathoracic space, and the prolonged learning curve associated with the procedure.
Beating-heart TECAB is accomplished with the aid of port-access myocardial stabilizers. The initial experience used a table-mounted stabilizer that was able to access only the anterior wall of the heart. Newer myocardial stabilizers that are mounted on the robotic instruments not only have made the procedure less technically challenging but have also facilitated access to the lateral and inferior walls of the ventricle, potentially affording the opportunity for more complete revascularization. Of note, however, relatively high perioperative morbidity and conversion rates for beating-heart TECAB have been reported. 29 The use of automated anastomotic connectors may help to make the procedure more consistent and reproducible.
The outcomes of the different types of robotic CABG are summarized in Table 2 . [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] It is important to note, however, that the majority of the reports are singlecenter series, in selected low-risk patient cohorts, with heterogeneous definitions, thus making direct comparison with conventional CABG difficult.
A recent meta-analysis on TECAB pooling data from 17 studies and 3721 patients reported a pooled event rate of 0.8% for operative mortality, 2.2% for perioperative myocardial infarction, 1.5% for perioperative stroke, and 2.9% for repeat revascularization and a 94.8% graft patency at a mean follow-up 10.1 months.
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MINIMALLY INVASIVE CABG
Minimally invasive coronary surgery (MICS CABG) was successfully developed as an extension of the excellent results reported for the minimally invasive direct CABG operation, which involved only single-vessel grafting of the LAD by the LITA through a small left thoracotomy.
In a recent meta-analysis of 14 studies and 446 patients undergoing minimally invasive direct CABG, the operative mortality was 1.3%, the rate of postoperative myocardial infarction was 2.9%, and the rate of target vessel repeat revascularization at 6 month was 3.2%. By combining specialized retractors that facilitate the visualization of both internal thoracic arteries and the ascending aorta, a cardiac apical positioner that allows manipulation of the heart to expose different coronary territories, an epicardial stabilizer to facilitate the coronary anastomoses, and optimization of intrathoracic and intracardiac pressures by experienced anesthesiologists, MICS CABG enables multivessel grafting of all myocardial territories with all types of conduits and graft configurations (Figure 4) . Most often, MICS CABG is performed without cardiopulmonary bypass.
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Observational studies have shown that MICS CABG is a safe alternative to CABG performed through a sternotomy. In 2009, McGinn et al 43 reported the safety and feasibility of MICS CABG in a prospective study of their dual-center experience of 450 patients. Complete revascularization was achieved in 95% of patients, with a mean of 2.1±0.7 grafts. Conversion to full sternotomy and operative mortality were low at 3.8% and 1.3%, respectively.
The 6-month angiographic patency was evaluated in the MICS CABG Patency Study, which enrolled 91 patients. 44 The overall graft patency was 92%, with 100% patency for LITA grafts and 85% for SVGs.
It must be noted, however, that, as for robotic CABG, most of the published series are retrospective observational studies with a small sample size, typically involving a single surgeon from a single center. Bias may also exist in patient selection, given the number of absolute and relative contraindications proposed in the early phase of these procedures.
In some studies, the number of grafts in MICS CABG patients is lower, which could reflect the enhanced ap- plicability of the procedure in single-or double-vessel disease but also could explain some differences in morbidity and postoperative recovery between MICS CABG and sternotomy CABG. The ongoing randomized MIST trial (Minimally Invasive Coronary Surgery Compared to Sternotomy Coronary Artery Bypass Grafting) will provide a higher level of scientific evidence on the results of MICS CABG.
COST ANALYSIS OF THE NEW METHODS FOR MYOCARDIAL REVASCULARIZATION
Because of the need for new devices and technology, there are concerns about increased cost for all the described new methods for myocardial revascularization. For the hybrid approach, a recent analysis showed that, compared with off-pump CABG, HCR results in a greater contribution margin for the hospital, resulting from mainly higher reimbursement and lower postoperative costs, which outweighs the more expensive procedural costs. 45 For similar reasons, the use of robotic CABG and MICS CABG has been shown not to be associated with increased in-hospital costs compared with traditional CABG.
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THE FUTURE OF TRADITIONAL CABG: ARTERIAL GRAFTS AND NO-TOUCH AORTA
The use of multiple AGs for CABG is certainly not new; the first series on the use of bilateral ITAs was published at the beginning of the CABG era. During the course of the last 20 years, multiple randomized controlled trials and meta-analyses have consistently reported that the patency rate of AGs is significantly higher than that of SVGs, especially in the midterm and long term. A network meta-analysis of 9 randomized controlled trials found that the use of an SVG increased the risk of midterm graft failure by 3-and 4-fold compared with the radial artery and the ITA, respectively. 47 However, controversies still exist about the clinical effect of the better patency rate of AGs. A large number of observational studies have reported that the use of multiple AGs is associated with better postoperative survival. Six meta-analyses have found significantly longer survival for patients who received bilateral versus single ITA for CABG. In the most recent, Buttar and associates 48 pooled data from 29 observational studies with a total of 89 399 patients and found a 22% relative reduction in the risk of follow-up death for the bilateral ITA arm.
However, surgeons are more likely to use multiple AGs in patients that they judge fit for surgery or with anticipated longer life expectancy on the basis of an unmeasurable (and unmatchable) "eyeballing." Consequently, concerns exist that, in observational series, treatment allocation bias, not biological superiority of AGs, may be the explanation for the better outcome of patients receiving >1 AGs. These concerns were reinforced after the neutral results of the interim analysis of ART (Randomized Trial of Bilateral Versus Single Internal-Thoracic-Artery Graft), the only large randomized controlled trial on the comparison between single and double ITA. 49 On the other hand, ART had methodological issues such as the possibly underpowered sample size, the liberal use of the radial artery in the single ITA group, and the high crossover rate that can potentially explain the failure of bilateral ITA grafts to improve clinical outcomes in the interim analysis.
Recently, a pooled analysis of patient-level data of all the randomized controlled trials comparing the radial artery and the SVG as the second conduit for CABG showed better midterm clinical outcome and patency rates for the radial artery group, providing the first randomized controlled trial-based demonstration of a clinical advantage associated with the use of multiple AGs. 50 A theory also suggests that AGs can protect the downstream coronary bed from atherosclerosis progression, probably through the production of anti-inflammatory and antithrombotic mediators. 51 A further evolution of the use of multiple AGs is the no-touch aorta (anaortic) CABG. Anaortic CABG implies off-pump CABG with the exclusive use of in-situ grafts (bilateral ITA, gastroepiploic artery, or Y grafts with the radial artery; Figure I in the online-only Data Supplement). By avoiding arterial cannulation and proximal aortic anastomoses of the bypass grafts, this technique minimizes, or even abolishes, aortic manipulation and the potential for intraoperative stroke. A recent network meta-analysis compared CABG with increasing degrees of aortic manipulation from on-pump CABG, off-pump CABG with a partial occlusion clamp, off-pump CABG with a "clampless" proximal anastomosis device, and anaortic CABG. 52 Anaortic CABG was significantly superior to all the other techniques in reducing stroke.
One of the most likely reasons for the limited adoption of anaortic CABG is the increased technical difficulty and the significant learning curve. In addition, little evidence on its efficacy has been published to date. Although a randomized controlled trial-based evaluation of the technique would be extremely important, the relatively low rate of clinical stroke after CABG would mandate a large, potentially unachievable, sample size to show differences between the groups.
CONCLUSIONS
In the 50 years since its introduction in clinical practice, CABG has undergone major changes. Although the basic principles of the operation have remained the same, technical and technological improvements have transformed the way the procedure is performed and perceived. In the modern era, coronary surgery is aimed at less invasive and more physiological operations and more durable results.
To date, the evidence supporting the use of hybrid, robotic, minimally invasive, and anaortic CABG is still very limited, whereas more information is available in support of the use of multiple AGs. However, several randomized controlled trials are currently investigating the results of the new modalities of surgical myocardial revascularization, and the next few years are likely to show a substantial revolution in the field of surgical myocardial revascularization.
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